<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The problem of cerebrovascular diseases prevention is currently urgent not only in neurology, but in the community as a whole, because of the leading rates of <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular diseases</z:e> in population disability and mortality </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0003124'>Hypercholesterolemia</z:hpo> is one of the corrected risk factors for the development of the given diseases </plain></SENT>
<SENT sid="2" pm="."><plain>The results of the study of 109 patients with CBI, II-III stages, treated with the drug <z:chebi fb="0" ids="50686">liprimar</z:chebi> and a new physiotherapeutic device, the neutralizer of free radicals, for cholesterol level optimization are presented </plain></SENT>
</text></document>